Related references
Note: Only part of the references are listed.
Article
Oncology
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Article
Medicine, General & Internal
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Article
Hematology
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Share Paper
